Literature DB >> 33315816

TRENDS IN INTRAVITREAL CORTICOSTEROID AGENT USE BY US OPHTHALMOLOGISTS IN MEDICARE BENEFICIARIES AND ASSOCIATION WITH PHYSICIAN-INDUSTRY INTERACTIONS.

Arjun Watane1, Meghana Kalavar1, Nicolas A Yannuzzi1, Ajay E Kuriyan2, Jayanth Sridhar1.   

Abstract

PURPOSE: To report trends of intravitreal corticosteroid use and explore the relationship between career experience, reported industry payments, and prescribing habits.
METHODS: A retrospective review of ophthalmologists who administered intravitreal dexamethasone implants (DEX) and triamcinolone acetonide (TA) injections between August 2013 and December 2017.
RESULTS: A total of 1,070 US ophthalmologists were reimbursed by Medicare for 522,804 DEX injections and 2.6 million TA injections. There was a significant positive trend in the number of DEX (P = 0.01), but not TA, injections per year. Mid-career and late-career physicians performed significantly greater total injections on average compared with early-career physicians (both P < 0.001). Early-career physicians performed a greater proportion of DEX injections than late-career physicians (P = 0.006). Industry payments were positively associated with the proportion of DEX used and inversely correlated with the proportion of TA administered (P < 0.001). On multivariate analysis, years in practice, number of payments, and total value of payments were significantly associated with the number of DEX injections administered (all P < 0.001).
CONCLUSION: From 2013 to 2017, the use of DEX increased, whereas TA use remained stable. There was a positive association between DEX use and physician-industry interactions, which may be explained by seniority and experience. This study does not define a causal relationship.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33315816      PMCID: PMC8190160          DOI: 10.1097/IAE.0000000000003081

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   3.975


  26 in total

1.  Gender differences in promotion and scholarly impact: an analysis of 1460 academic ophthalmologists.

Authors:  Santiago A Lopez; Peter F Svider; Poonam Misra; Neelakshi Bhagat; Paul D Langer; Jean Anderson Eloy
Journal:  J Surg Educ       Date:  2014-05-20       Impact factor: 2.891

2.  Steroid differentiation: the safety profile of various steroids on retinal cells in vitro and their implications for clinical use (an American Ophthalmological Society thesis).

Authors:  Baruch D Kuppermann; Leandro Cabral Zacharias; M Cristina Kenney
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

3.  A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5.

Authors:  Michael S Ip; Ingrid U Scott; Paul C VanVeldhuisen; Neal L Oden; Barbara A Blodi; Marian Fisher; Lawrence J Singerman; Michael Tolentino; Clement K Chan; Victor H Gonzalez
Journal:  Arch Ophthalmol       Date:  2009-09

4.  Intravitreal triamcinolone acetonide: a "real world" analysis of visual acuity, pressure and outcomes.

Authors:  Victor Manuel Villegas; Aaron Samuel Gold; Andrea Wildner; Azeema Latiff; Timothy Garrett Murray
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

5.  Changes in real-world treatment patterns for diabetic macular oedema from 2009 to 2019 and 5-year outcomes: Data from the Fight Retinal Blindness! Registry.

Authors:  Anne C Biechl; Sanjeeb Bhandari; Vuong Nguyen; Jennifer J Arnold; Stephanie Young; Samantha Fraser-Bell; Hemal Mehta; Mark Gillies; Daniel Barthelmes
Journal:  Clin Exp Ophthalmol       Date:  2020-06-11       Impact factor: 4.207

6.  Real-World Assessment of Dexamethasone Intravitreal Implant in DME: Findings of the Prospective, Multicenter REINFORCE Study.

Authors:  Michael A Singer; Pravin U Dugel; Howard F Fine; Antonio Capone; John Maltman
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2018-06-01       Impact factor: 1.300

7.  Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema.

Authors:  David S Boyer; Young Hee Yoon; Rubens Belfort; Francesco Bandello; Raj K Maturi; Albert J Augustin; Xiao-Yan Li; Harry Cui; Yehia Hashad; Scott M Whitcup
Journal:  Ophthalmology       Date:  2014-06-04       Impact factor: 12.079

8.  Evaluation of Efficacy and Safety of Dexamethasone Intravitreal Implants of Vitrectomized and Nonvitrectomized Eyes in a Real-World Study.

Authors:  Amina Rezkallah; Ariane Malclès; Corinne Dot; Nicolas Voirin; Émilie Agard; Anne-Laure Vié; Philippe Denis; Thibaud Mathis; Laurent Kodjikian
Journal:  J Ocul Pharmacol Ther       Date:  2018-08-17       Impact factor: 2.671

9.  A national survey of physician-industry relationships.

Authors:  Eric G Campbell; Russell L Gruen; James Mountford; Lawrence G Miller; Paul D Cleary; David Blumenthal
Journal:  N Engl J Med       Date:  2007-04-26       Impact factor: 91.245

Review 10.  INTRAVITREAL CORTICOSTEROIDS IN DIABETIC MACULAR EDEMA: PHARMACOKINETIC CONSIDERATIONS.

Authors:  Yit Yang; Clare Bailey; Anat Loewenstein; Pascale Massin
Journal:  Retina       Date:  2015-12       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.